



Contacts: Susan Lehman
Rockpoint Public Relations
+1 (510) 832-6006
susan@rockpointpr.com

Stephanie Tomei
Public Relations Manager
+1 (408) 789-4234
stomei@accuray.com

CyberKnife Radiosurgery Expands to India

First System Purchased for Installation in Bangalore

SUNNYVALE, Calif, January 8, 2008– Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Healthcare Global Enterprise (HCG) has purchased a CyberKnife[®] Robotic Radiosurgery System for its new oncology center in Bangalore, India. Upon installation in June 2008, this will be the first CyberKnife System in India, expanding treatment access to this burgeoning market.

“Introducing CyberKnife treatment to India for the first time is a huge milestone in achieving broader access to the benefits of radiosurgery,” said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. “The CyberKnife System that will be installed in Bangalore will provide an innovative, non-invasive cancer treatment option to the more than one million patients diagnosed with cancer in India every year.”

Recognizing the importance and rapid growth of the radiation oncology market in India, Accuray has established a wholly-owned subsidiary headquartered in New Delhi.

About the CyberKnife[®] Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-Q for the quarterly period ended September 29, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

###